Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

BACKGROUND: To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients with MBC and HER2-positive CTCs despite disease stabilization or response to prior therapy, rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Agelaki, Sofia, Kalykaki, Antonia, Markomanolaki, Harris, Papadaki, Maria A., Kallergi, Galatea, Hatzidaki, Dora, Kalbakis, Kostas, Mavroudis, Dimitrios, Georgoulias, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471111/
https://www.ncbi.nlm.nih.gov/pubmed/26083256
http://dx.doi.org/10.1371/journal.pone.0123683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471111/
https://www.ncbi.nlm.nih.gov/pubmed/26083256
http://dx.doi.org/10.1371/journal.pone.0123683

Ejemplares similares